EAM
UROV

Eventide Asset Management’s Urovant Sciences Ltd. UROV Stock Holding History

Eventide Asset Management’s Portfolio UROV Stock Details UROV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-401,558
Closed -$3.18M – 136
2019
Q2 		$3.18M Sell
401,558
-267,442
-40% -$2.19M 0.1% 92
2019
Q1 		$6.72M Hold
669,000
– – 0.23% 82
2018
Q4 		$4.41M Buy
669,000
+74,184
+12% +$675K 0.2% 88
2018
Q3 		$7.14M Buy
+594,816
New +$7.03M 0.26% 89

Other funds holding UROV

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WCM
Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Eventide Asset Management's UROV Position: Q3 2019 in Review

Eventide Asset Management sold out of Urovant Sciences Ltd. (UROV) in Q3 2019, closing a stake of 401,558 shares — an estimated $3.18M sold.

Eventide Asset Management first reported a position in UROV in Q3 2018 and held it in 4 quarters. The position peaked at $7.14M in Q3 2018. 27 funds tracked by Wall St. Rank hold UROV as of Q3 2019.

  • Eventide Asset Management reported no remaining Urovant Sciences Ltd. position as of Q3 2019 after selling out during the quarter.
  • Eventide Asset Management sold 401,558 Urovant Sciences Ltd. shares in Q3 2019, an estimated $3.18M.
  • Eventide Asset Management first reported a position in Urovant Sciences Ltd. in Q3 2018 and held it in 4 quarters.
  • Eventide Asset Management's Urovant Sciences Ltd. position peaked at $7.14M in Q3 2018.
  • 27 funds tracked by Wall St. Rank held Urovant Sciences Ltd. as of Q3 2019.

Based on Eventide Asset Management's 13F filing for Q3 2019, filed 21 Nov 2019.